gip glp 1 tirzepatide Microdosed Tirzepatide vs Semaglutide | Understanding

The incidence rate varies but is estimated to be between 5 and 80 cases per 100,000 people annually

Rybelsus stands apart as an oral tablet, offering an attractive option for individuals who may have reservations about injections

Changes in respiratory function People with diabetes are at a higher risk of respiratory conditions, such as sleep apnoea, asthma, and chronic obstructive pulmonary disease (COPD)

Food and Drug Administration (FDA) approved Novo Nordisk's Wegovy pill as the first and only oral GLP-1 therapy indicated to reduce excess body weight, support long-term weight maintenance, and reduce the risk of certain major adverse cardiovascular events.1 FDA approval of the Wegovy pill was supported by a 64-week Phase 3 trial showing weight loss efficacy unmatched by other oral GLP-1 candidates, with once-daily treatment plus diet and exercise achieving 16.6% mean weight loss versus 2.7% with placebo.2 The availability of an oral formulation is expected to broaden access to GLP1 treatment by offering an alternative option for patients who may be hesitant to initiate or continue weekly injections

Still, studies show that it also helps people without diabetes lose weight